A Phase I Trial of Oxaliplatin, Irinotecan, and S-1 Combination Therapy (OX-IRIS) as Chemotherapy for Unresectable Pancreatic Cancer (HGCSG 1403)

[摘要] Lessons Learned Because S-1 is orally administered, OX-IRIS does not necessitate the continuous infusion of 5-FU and is more convenient. The recommended dose of OX-IRIS was determined to be level −1 (oxaliplatin, 65 mg/m 2 ; irinotecan, 100 mg/m 2 ; S-1, 80 mg/m 2 ), which has manageable safety and promising anticancer activities.

[学科分类] 地质学

[关键词] Pancreatic cancer;Combination therapy;Oxaliplatin;Irinotecan;S-1